Introduction {#S1}
============

Prosthetic valve thrombosis (PVT) is one of the major complications of mechanical prosthetic heart valve replacement. Pregnancy is associated with increased risk of thrombosis among women with mechanical prosthetic heart valves \[[@B1]\]. Thrombolytic therapy (TT) has evolved as an effective alternative to surgery, which is associated with very high maternal and fetal mortality and morbidity in pregnant patients with PVT \[[@B2], [@B3]\]. The most feared complication during TT of left-sided PVT is cerebral thromboembolism. We present a pregnant patient who was complicated with cerebral thromboembolism during TT for PVT and successfully managed with continuation of TT.

Case Presentation {#S2}
=================

A 28-year-old woman who had undergone mitral valve replacement 8 years earlier was admitted to our hospital with dyspnea. She was pregnant for 6 months and under anticoagulant therapy with low moleculer weight heparin for 6 months. Transthoracic echocardiography (TTE) and subsequently two-dimensional (2D) and real-time three-dimensional (RT3D) transesophageal echocardiography (TEE) were performed for the evaluation of prosthetic mitral valve. TTE revealed high transmitral gradients (maximum/mean: 37/23 mmHg) and decreased valve area (1.1 cm^2^) with normal left ventricular ejection fraction. Subsequently, 2D and RT3D TEE showed an obstructive thrombus on the mitral prosthesis *(Fig. [1A](#fig1){ref-type="fig"}* and *[1B](#fig1){ref-type="fig"})*. After the informed consent of the patient was taken, TT was started with a protocol of low dose (25 mg) and ultraslow infusion (25 h) of tissue-type plasminogen activator (tPA), as recently reported \[[@B3]\]. After the first session of TT, TEE revealed a decrease in the thrombus burden; however, there was a mobile residual thrombus (10 mm in length) on the mitral prosthesis. Based upon these findings, a second session of TT was scheduled. During the second session of TT, acute stroke occurred that resulted in right hemiplegia. Cerebral multidetector computed tomography (MDCT) angiography was urgently performed with fetal radiation protection. MDCT angiography revealed thrombotic occlusion of left middle cerebral artery (MCA) without any sign of hemorrhage *(Fig.* [*2A*](#fig2){ref-type="fig"}--*[2C](#fig2){ref-type="fig"})*. After an immediate consultation with a neurologist and radiologist, TT was restarted with an accelerated rate (25 mg/2 h) of infusion. The hemiplegia was completely resolved and MDCT showed normal MCA perfusion at the end of two accelerated sessions within 4 h *(Fig.* *[2D](#fig2){ref-type="fig"})*. Subsequently, control 2D and RT3D TEE revealed complete lysis of the thrombus on the mitral prosthesis *(Fig.* [*1C*](#fig1){ref-type="fig"} and *[1D](#fig1){ref-type="fig"})*. At the end of 38th week of pregnancy, a healthy baby was delivered.

![Two-dimensional (A) and real-time three-dimensional (B) transesophageal echocardiography showed an obstructive thrombus on the mitral prosthesis on admission and complete lysis of the thrombus after thrombolytic therapy (C and D)](imas-09-03-30_f001){#fig1}

![Cerebral multidetector computed tomography (MDCT) angiography revealed thrombotic occlusion of left middle cerebral artery (MCA) without any sign of hemorrhage (A--C). The MCA occlusion was successfully recanalized after thrombolytic therapy (D)](imas-09-03-30_f002){#fig2}

Discussion {#S3}
==========

PVT is one of the major causes of prosthetic valve dysfunction. Treatment modalities for PVT include anticoagulation with heparin, TT, and surgery. Surgery is suggested as a first-line strategy in most situations of left-sided PVT; however, multiple recent non-randomized studies have shown the efficacy and safety of low dose and slow infusion thrombolysis in patients with left-sided PVT in most patients \[[@B1]\]. Hence, the American College of Cardiology/American Heart Association Focused Update on Valvular Heart Disease Guidelines now equally recommends (Class 1B) urgent thrombolysis or surgery for obstructive PVT as first-line treatment strategy \[[@B5]\].

Pregnancy is associated with increased risk of thrombosis among women with mechanical prosthetic heart valves. PVT in pregnancy is a life-threatening event for both mother and fetus and treatment of this complication is unclear. Although no evidence-based guidelines for pregnant patients complicated with PVT are currently available, recommendations of guidelines for this complication are similar to the management of PVT in non-pregnant patients.

We have previously reported that repeated doses of low dose (25 mg) and slow infusion (6 h) of tPA under the guidance of serial TEE was superior to faster infusion and/or higher dose protocols or streptokinase \[[@B1]\]. This protocol provided excellent results even in pregnant patients with PVT \[[@B2]\]. In addition, we have very recently reported that ultraslow (25 h) infusion of low dose (25 mg) tPA without bolus appears to be associated with quite low complications and mortality rates for PVT patients without compromising post-thrombolytic success \[[@B3]\].

Cerebral thromboembolism may rarely occur during TT for PVT \[[@B6]\]. The first 6 h after cerebral thromboembolism are very substantial and early diagnosis and exclusion of hemorrhage by MDCT is very important \[[@B7]\]. Acute ischemic stroke may be managed with intravenous thrombolysis, combination of thrombolytics with other antiaggregants like glycoprotein IIb/IIIa inhibitors, intraarterial thrombolysis, and other catheter-based approaches, such as mechanical thrombectomy \[[@B8], [@B9]\]. This is the second case reported by our team emphasizing that continuation of TT with an accelerated protocol may provide a chance for successful lysis of both valvular and cerebral thrombosis for such patients who suffer acute ischemic stroke during TT.

In current case, a decision was made in favor of continuing TT on top of TT, which resulted in striking neurological improvement. The recommended tPA dose for acute ischemic stroke regarding current guidelines is 0.9 mg/kg (maximum dose 90 mg) over 60 min with 10% of the dose given as a bolus over 1 min \[[@B7]\]. Although the protocol we used was lower than the recommended doses for safety concerns, the success may be due to the early diagnosis and fresh nature of the thrombus. Faster TT regimens may induce new thromboembolisms in patients with concomitant PVT.
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